摘要
背景:目前很少有数据介绍帕唑帕尼治疗患有肾癌细胞经历透析患者的研究,并且过去在此方面也没有进行系统性的研究。 目的:本文迷你研究的目的是为了整体回顾一下帕唑帕尼在人体实验的临床试验结果,为临床肿瘤学家制定更好的临床选择和管理提供参考。 结果:直至2015年8月,评估所有发行的与肾癌细胞透析患者接受帕唑帕尼治疗相关的文献,发现在我们的搜索中,在所有11位肾癌细胞透析患者中仅有两个案例,这其中包括来自我们部门中的一个患者。并且,我们描述了帕唑帕尼在透析过程中剂量调整的案例。 结论:继续治疗计划、短半衰期、主要肝代谢、剂量调整的广泛可能性、良好的耐药性以及与舒尼替尼类似的效果这些代表因素支持帕唑帕尼作为透析患者一线肾癌细胞治疗方案。在帕唑帕尼对透析患者治疗过程中毒性的认知和好的管理也能引导药物更好、更长久的应用,考虑到由毒性引导的剂量升级的概念可作为疗效的标记。本文结合我们的案例报告,确认了帕唑帕尼治疗肾癌细胞透析患者的疗效、良好的耐受性和可操作性。
关键词: 透析;剂量调整;血液透析;帕唑帕尼;胃癌细胞;酪氨酸激酶抑制剂
Current Drug Targets
Title:Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report
Volume: 17 Issue: 15
Author(s): Melissa Bersanelli, Francesco Facchinetti, Marcello Tiseo, Mariarosa Maiorana, Sebastiano Buti
Affiliation:
关键词: 透析;剂量调整;血液透析;帕唑帕尼;胃癌细胞;酪氨酸激酶抑制剂
摘要: Background: Sporadic data are available about pazopanib use in patients with metastatic renal cell carcinoma (mRCC) undergoing dialysis and no systematic review has been previously performed about this issue.
Objective: The objective of the present mini-review is to provide an overview of clinical outcomes of pazopanib in this population, in order to support the clinical oncologist for the treatment choice and management.
Results: All the literature ever published about mRCC dialysis patients receiving pazopanib, until August 2015, was evaluated: only two case series emerged from our search and one more patient from our department was also included, with a total of 11 mRCC dialysis patients overall. Moreover, we described our case of intrapatient dose titration of pazopanib during dialysis.
Conclusion: The continued treatment schedule, the short half-life, the predominantly hepatic metabolism, the wide possibility of dose modulation, the favorable tolerability profile and the similar efficacy respect to sunitinib represent factors in favor of pazopanib as first line mRCC treatment in dialysis patients. The knowledge and the good management of toxicity during pazopanib treatment can lead, also in dialysis patients, to the best and longest application of the drug, taking into account the concept of a dose escalation guided by toxicity as a marker of efficacy. The review, together with our single case report, confirmed the efficacy, the good tolerability and the maneuverability of pazopanib treatment in mRCC patients undergoing dialysis.
Export Options
About this article
Cite this article as:
Melissa Bersanelli, Francesco Facchinetti, Marcello Tiseo, Mariarosa Maiorana, Sebastiano Buti , Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report, Current Drug Targets 2016; 17 (15) . https://dx.doi.org/10.2174/1389450117666160112114756
DOI https://dx.doi.org/10.2174/1389450117666160112114756 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
Current Topics in Medicinal Chemistry Treatment of MDR1 Mutant Dogs with Macrocyclic Lactones
Current Pharmaceutical Biotechnology Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection
Reviews on Recent Clinical Trials Progress Towards Recombinant Anti-Infective Antibodies
Recent Patents on Anti-Infective Drug Discovery Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design The Water Channels, New Druggable Targets to Combat Cancer Cell Survival,Invasiveness and Metastasis
Current Drug Targets Engagement of Renin-Angiotensin System in Prostate Cancer
Current Cancer Drug Targets Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry Recent Advances of Natural and Synthetic β-Carbolines as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences Strategies for Development of Antimalarials Based on Encapsulated Porphyrin Derivatives
Mini-Reviews in Medicinal Chemistry Biophysical Modeling and Associated Signal Modeling in Functional Magnetic Resonance Imaging
Neuroscience and Biomedical Engineering (Discontinued) Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Current Molecular Medicine Tumor Immune Escape Mechanisms that Operate During Metastasis
Current Pharmaceutical Biotechnology Blood-Brain Barrier Penetration and Drug Development from an Industrial Point of View
Current Medicinal Chemistry - Central Nervous System Agents In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells
Current Cancer Drug Targets The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy